Ablynx Begins Pre-Clinical Development of Anti-IgE Nanobody, ALX-0962 to Treat …

Published May 25, 2013

Ablynx begins pre-clinical development of anti-IgE nanobody, ALX-0962 to treat …
Filed under: dual diagnosis drug treatment

Due to the Nanobody's unique and dual mode of action, we believe ALX-0962 could take an important share of this very large market not least by offering a treatment option to patients not eligible for currently available IgE inhibiting drugs." ALX-0962 …
{Source}

Merck Pharmaceuticals' Suvorexant: A Wake-Up Call
Filed under: dual diagnosis drug treatment

Merck is attempting a new method of treatment by avoiding this portion of the brain. Its new drug, Suvorexant, attempts to block chemicals called orexins, which are mostly responsible for keeping people awake. This class of drug is known as Dual Orexin …
{Source}